Private Provision of Social Insurance: Drug-Specific Price Elasticities and Cost Sharing in Medicare Part D

doi 10.3386/w22277
Full Text
Abstract

Available in full text

Date
Authors
Publisher

National Bureau of Economic Research

Related search

Radiation Oncology Drug Prescription Patterns in Medicare Part D

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D

2015English

Evaluation of Social Welfare Part of Hungarian Drug Provision System

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Cost Minimization Analysis of Equipotent Opioid Analgesics: Nationwide Analysis of Medicare Part D Stand-Alone Prescription Drug Plans

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Gabepentinoids and Benzodiazepines in Medicare Part D

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2018English

Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017

JAMA - Journal of the American Medical Association
Medicine
2019English

Cost-Related Medication Nonadherence Among Beneficiaries With Depression Following Medicare Part D

American Journal of Geriatric Psychiatry
PsychiatryGerontologyGeriatricsMental Health
2009English

The Impact of Health Insurance Expansion on Physician Treatment Choice: Medicare Part D and Physician Prescribing

2014English

Should Drug Prices Be Negotiated Under Part D of Medicare? And if So, How?

Health Affairs
MedicineHealth Policy
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy